Tailoring response-based treatment for hepatitis C

Ho, A. and Fox, R. (2011) Tailoring response-based treatment for hepatitis C. Viral Hepatitis in Practice, 3(1), pp. 1-5.

Full text not currently available from Enlighten.

Publisher's URL: http://www.vhip.co.uk/_year_search_review.aspx?JID=10&Year=2011&Edition=133

Abstract

The recommended treatment for chronic infection with hepatitis C virus (HCV) is a combination of pegylated interferon (pegIFN) alfa and ribavirin (RBV). Treatment duration is determined by HCV genotype: in genotype 1 (G1) infection, treatment usually lasts for 48 weeks, whereas in genotypes 2 and 3 (G2, G3), therapy for 24 weeks has been found to have equivalent efficacy.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Ho, Dr Antonia
Authors: Ho, A., and Fox, R.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Viral Hepatitis in Practice
Publisher:Hayward
ISSN:2041-1162
ISSN (Online):2045-7863

University Staff: Request a correction | Enlighten Editors: Update this record